Anorectic state of obesity medications in the United States. Are leaner times ahead?

Research output: Contribution to journalArticle

Abstract

Introduction: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management. Areas covered: This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known. Expert opinion: Despite obesity being a chronic condition affecting 40% of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need.

Original languageEnglish (US)
Pages (from-to)167-172
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume21
Issue number2
DOIs
StatePublished - Jan 22 2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology

Keywords

  • MEDI0382
  • Orlistat
  • dapagliflozin
  • liraglutide
  • lorcaserin
  • naltrexone/bupropion
  • phentermine/topiramate
  • semaglutide
  • setmelanotide
  • tesofensine

Fingerprint Dive into the research topics of 'Anorectic state of obesity medications in the United States. Are leaner times ahead?'. Together they form a unique fingerprint.

  • Cite this